There is need to better match cancer treatment to Purpose: To evaluate candidate fluorodeoxyglucose positron emission tomography/ computed tomography (FDG-PET/CT) imaging biomarkers for head-and-neck chemoradiotherapy outcomes in the cooperative group trial setting. Methods and Materials: Radiation Therapy Oncology Group (RTOG) protocol 0522 patients consenting to a secondary FDG-PET/CT substudy were serially imaged at baseline and 8 weeks after radiation. Maximum standardized uptake value (SUVmax), SUV peak (mean SUV within a 1-cm sphere centered on SUVmax), and metabolic tumor volume (MTV) using 40% of SUVmax as threshold were obtained from primary tumor and involved nodes. Results: Of 940 patients entered onto RTOG 0522, 74 were analyzable for this substudy. Neither high baseline SUVmax nor SUVpeak from primary or nodal disease were associated with poor treatment outcomes. However, primary tumor MTV above the cohort median was associated with worse local-regional control (hazard ratio 4.01, 95% confidence interval 1.28-12.52, PZ.02) and progression-free survival (hazard ratio 2.34, 95% confidence interval 1.02-5.37, PZ.05). Although MTV and T stage seemed to correlate (mean MTV 6.4, 13.2, and 26.8 for T2, T3, and T4 tumors, respectively), MTV remained a strong independent prognostic factor for progression-free survival in bivariate analysis that included T stage. Primary MTV remained prognostic in p16-associated oropharyngeal cancer cases, although sample size was limited. Conclusion: High baseline primary tumor MTV was associated with worse treatment outcomes in this limited patient subset of RTOG 0522. Additional confirmatory work will be required to validate primary tumor MTV as a prognostic imaging biomarker for patient stratification in future trials. Ó
individual patient risk. Tumor imaging provides a means to define disease phenotype and treatment response. Predefined study objectives of the recently concluded RTOG 0522 trial included correlation of PET/ CT findings with treatment outcomes. In this report we describe a potential prognostic signal for primary tumor FDG-PETederived MTV in patients with locally advanced head-and-neck cancer. This finding remains preliminary and requires further confirmation.
Methods and Materials: Radiation Therapy Oncology Group (RTOG) protocol 0522 patients consenting to a secondary FDG-PET/CT substudy were serially imaged at baseline and 8 weeks after radiation. Maximum standardized uptake value (SUVmax), SUV peak (mean SUV within a 1-cm sphere centered on SUVmax), and metabolic tumor volume (MTV) using 40% of SUVmax as threshold were obtained from primary tumor and involved nodes. Results: Of 940 patients entered onto RTOG 0522, 74 were analyzable for this substudy. Neither high baseline SUVmax nor SUVpeak from primary or nodal disease were associated with poor treatment outcomes. However, primary tumor MTV above the cohort median was associated with worse local-regional control (hazard ratio 4.01, 95% confidence interval 1.28-12.52, PZ.02) and progression-free survival (hazard ratio 2.34, 95% confidence interval 1.02-5.37, PZ.05). Although MTV and T stage seemed to correlate (mean MTV 6.4, 13.2, and 26.8 for T2, T3, and T4 tumors, respectively), MTV remained a strong independent prognostic factor for progression-free survival in bivariate analysis that included T stage. Primary MTV remained prognostic in p16-associated oropharyngeal cancer cases, although sample size was limited. Conclusion: High baseline primary tumor MTV was associated with worse treatment outcomes in this limited patient subset of RTOG 0522. Additional confirmatory work will be required to validate primary tumor MTV as a prognostic imaging biomarker for patient stratification in future trials. Ó 2015 Elsevier Inc. All rights reserved.
Introduction
Effective patient selection drives successful clinical cancer trial design. Tissue-based biomarkers have been used toward this end, with a promise to increase study power and reduce treatment development costs. However, tumor tissue collection is expensive and burdensome. Tumor imaging provides an alternative means to noninvasively define disease phenotype and treatment response.
Functional imaging delivers quantitative characterization of tumor and host tissue physiology. Fluorodeoxyglucose positron emission tomography (FDG-PET), with or without coregistered computed tomography (CT), serves as the traditional "work horse" for functional head-and-neck imaging. Published experience with FDG-PETedefined staging is mature and has been summarized by meta-analyses (1), expert consensus reports (2, 3), and comparative effectiveness studies (4) . Imaging by FDG-PET incrementally improves staging accuracy and treatment response assessment over anatomic imaging (5) (6) (7) (8) , particularly if guided by complementary clinical features (9, 10) . Some institutional series suggest that certain FDG-PET parameters, such as the maximum or peak standardized uptake values (SUVs), may serve as quantifiable imaging biomarkers for radiation therapy outcomes (11) (12) (13) . However, conflicting reports refute the predictive value of SUV (14) , and quantitative head-andneck FDG-PET outcome measures remain untested in the cooperative group trial setting.
Radiation Therapy Oncology Group (RTOG) protocol 0522 recently completed enrollment of 940 patients diagnosed with locally advanced head-and-neck cancer. Study subjects received concurrent radiation therapy and cisplatin, with or without the addition of cetuximab. All RTOG 0522 subjects with N2-3 disease (with the exception of N2c with both sides N1) were eligible for baseline and posttreatment coregistered PET/CT imaging analysis. Predefined study objectives included correlation of pre-and posttreatment PET/CT scan findings with histologic findings of neck dissection specimens and treatment outcomes. Given interval publication of encouraging institutional pilot findings for use of FDG-PETedefined metabolic tumor volume (MTV) as an imaging biomarker for radiation therapy treatment response and tumor control outcomes (15) (16) (17) , MTV was included as a secondary post hoc study objective in the present report.
Methods and Materials

Study population
Patients enrolled to RTOG 0522 with N2a, N2b, N2c (with right and/or left side N2a-N2b), or N3 disease, who agreed to participate in the PET/CT study, and for whom at least 1 PET image set was available for central review, were included in this analysis.
PET/CT image and scanner compatibility requirements
All centers participating in this imaging study had to provide 1 test case to the American College of Radiology Imaging Network (ACRIN) PET Core Laboratory before start of enrollment to credential their file transfer capabilities and image quality. The PET Core Laboratory provided software for imaging facilities to collect, deidentify, and submit image sets either from a PET/CT scanner or a picture archiving and communication system (PACS) to the ACRIN image archive. All imaging had to be performed on a combined PET/CT instrument with full ring PET and 4-slice or greater multidetector CT operating in highsensitivity 2-dimensional mode, if available. To simplify multi-institutional participation, centers were not required to use uniform PET/CT software. Three-dimensional mode was permissible for patients imaged on combined PET/CT scanners without a 2-dimensional mode.
Patient preparation and FDG injection
Participating centers were instructed to record patient height and weight before each PET scan, to have patients observe a 4-to 6-hour fasting period before FDG injection, and to measure serum glucose concentration before scanning. A serum glucose value <200 mg/dL was necessary to proceed to imaging. Centers were instructed to inject a dose of 10 to 20 mCi of FDG intravenously and to begin imaging within 50 to 70 minutes after tracer administration.
Baseline and posttreatment PET/CT imaging
Imaging was required to encompass the vertex of the head down through the entire pelvis. The recommended imaging protocol incorporated 2 discrete phases: during the first phase, head-and-neck scanning was performed with arms resting at sides and full neck extension using a 120 keV/ 300 mA, 0.5-second detector rotation time ("high mA") CT scan with intravenous contrast (100 mL contrast bolus administered at 1.5 mL/s, with a 50-second scan delay and with the scan started inferiorly, moving cranially), followed by a 120 keV/80 mA, 0.8-second detector rotation time ("low mA") CT scan for PET attenuation correction, followed last by PET scanning. Standard manufacturer recommendations for specific low and high mA CT scanning parameters could be substituted. Two fields of view (approximately 15 cm) were required for full head-and-neck PET imaging from manubrium to vertex. Centers were instructed to allow patients to rest their neck for 1 to 2 minutes. For the second phase of imaging, the neck was shifted into neutral position, and the remainder of the body was surveyed per routine local institutional protocol with arms raised above the head to allow for thoracic and abdominal imaging. At least 4 to 5 PET fields of view were to be used for this phase. The PET data were corrected for dead time, scatter, random coincidence events, and attenuation, and ultimately reconstructed into images via the filtering algorithm provided by the scanner manufacturer. A posttreatment FDG-PET/CT scan was recommended 8 to 9 weeks after completion of treatment (in addition to mandatory CT or magnetic resonance posttreatment imaging). Centers were requested to perform posttreatment PET/CT imaging in this time frame and on the same scanner, if possible.
Maximum SUV (SUVmax), Peak SUV (SUVpeak), and MTV
The SUV normalized by specific injected dose and patient weight was calculated on centralized review by 2 head-andneck radiation oncologists with specific expertise in PET/ CT interpretation (D.L.S. and M.Y.) using commercial image analysis software (MIM Software, v.5.2, Cleveland, OH). Detection of primary and nodal disease by FDG-PET/ CT was determined qualitatively as FDG uptake greater than surrounding normal soft tissue within a CT-delineated anatomic (primary disease or nodal) abnormality. The SUVmax was defined as (tissue activity) (mCi/mL)/(injected dose) (mCi)/(patient weight) (kg) within the voxel having the highest activity within a given region of interest (ROI). These values were determined separately for ROIs within primary tumor and involved cervical lymph nodes. Each ROI had to encompass the entire FDG-avid lesion of interest, with boundaries guided by CT delineation. The SUVpeak for primary and nodal disease was measured from a 1-cm 3 sphere centered on the voxel with the highest mean SUV value. The location of this sphere was manually checked to ensure reasonable position within disease. Primary tumor MTV contours were generated from voxels that were 40% of primary SUVmax. A specific tumor can have a much higher SUV than another tumor, but MTV calculations and volume generation will remain consistent across tumors because the analysis tool performs identical calculations of proportionality regardless of baseline SUVmax value. Nodal MTV was measured separately for each side of the neck, inclusive of all metabolically active nodes (including cystic regions within these nodes), and defined as the nodal tumor volume above 40% of the nodal SUVmax. For bilateral neck disease, the maximum of right and left sides was used for SUV and the sum for MTV. Total MTV, defined as primary MTV plus nodal MTV, was calculated for patients with both measures.
Data analysis and statistics
The following pre-and posttreatment PET values were obtained from central review: SUVmax, SUVpeak, and MTV of the primary tumor, right nodal disease, and left nodal disease. The protocol analysis plan prespecified the analysis of SUV measures. Evaluation of MTV represents post hoc secondary analysis and must be formally considered exploratory in nature. The study cohort was dichotomized into equal-size comparator groups by median PET values to maximize statistical power for analysis. Patients with at least one readable value from either reader were included. Consistency between readers was measured by intraclass correlation coefficient.
Clinical endpoints specified by the trial protocol were local relapse (including salvage surgery for primary site with tumor present/unknown), regional relapse (including neck dissection >15 weeks after the end of radiation therapy with tumor present/unknown), localeregional relapse, distant metastasis, progression-free survival, and overall survival. Only death was considered a competing risk for local relapse, regional relapse, localeregional relapse, or distant metastasis. Progression-free survival Volume 91 Number 4 2015 events were defined as local or regional relapse, distant metastasis, or death due to any cause. All endpoints were measured from the date of randomization. Rates for local, regional, and localeregional relapse, and distant metastasis were estimated by the cumulative incidence method (18) , and rates for progression-free and overall survival were estimated by the Kaplan-Meier method (19) . Hazard ratios were estimated by Cox proportional hazards models (20) . To address whether negative (SUVmax <3, per Yao et al [21] ) posttreatment PET/CT in patients who achieve a clinical complete nodal response (CR, defined as no evidence of nodal disease on physical examination and/or imaging) predicts for a low nodal relapse rate (<10%) at 2 years, the 2-year regional relapse rates in 4 groups were calculated: (1) clinical CR, negative PET; (2) clinical < CR, negative PET; (3) clinical CR, positive PET; and (4) clinical < CR, positive PET.
Exploratory post hoc subgroup analysis was performed to selectively evaluate PET measures in patients with p16-positive oropharyngeal cancer. Missing p16 values were imputed 20 times using conditional model specification for multivariate imputation via Gibbs sampling (22) , and the resulting datasets were combined using Rubin's formula (23) , and sensitivity analyses were conducted to validate the robustness of the imputation procedure. Akaike information criterion (24) was used to measure the relative quality of our statistical models.
Results
Imaging study cohort
One hundred sixteen patients agreed to participate in the PET/CT study. Forty-two subjects did not follow through with posttreatment imaging or had unreadable image files, yielding 74 patients from 19 centers with both preand posttreatment PET/CT imaging available for this analysis. In addition, 535 patients were eligible for the PET/CT study according to N stage but chose not to participate, for a total of 577 patients not included in this analysis. Analyzed patients enjoyed better performance status and shorter pack-year tobacco exposure but presented at a more advanced T stage than excluded patients (Table 1) . At the time of analysis, median follow-up for surviving patients (58 of 74) was 4.2 years (range, 3.1-6.2 years).
PET summary and reviewer agreement
Summary FDG-PET/CT outcome measures are listed in Table 2 
Correlation of baseline SUV values with treatment outcomes
Elevated baseline primary/nodal FDG SUVmax or SUVpeak values above median value of the study cohort were not associated with poor clinical outcomes (Table 3 ). This also held true when either value was alternatively analyzed as a continuous variable (data not shown). 
Correlation of posttreatment SUV values with nodal response
Correlation of baseline MTV with treatment outcomes
Pretreatment primary MTV above the study cohort median was associated with localeregional relapse (hazard ratio 4.01, 95% CI 1.28-12.52, PZ.02) and poorer progressionfree survival (hazard ratio 2.34, 95% CI 1.02-5.37, PZ.05) (Fig. 1, Table 4 ). Elevated baseline nodal MTV values, on the other hand, were nonprognostic. Results for combined primary and nodal MTV were similar to primary MTV alone (hazard ratio for progression-free survival 2.37, 95% CI 0.99-5.69, PZ.05). Primary MTV and total MTV were highly correlated (Spearman correlation 0.78 on the raw values; 4 coefficient 0.57 for measures dichotomized by group median). Table E1 (available online at www.redjournal.com) presents summary statistics for primary MTV by T stage. The mean primary MTV roughly doubled with each upstage: T2 6.39, T3 13.24, T4, 26.79. Primary MTV was a stronger prognostic factor than T stage for localeregional relapse and progression-free survival ( Table 5 ). The hazard ratios for primary MTV changed little when T stage was added to a bivariate model, but T stage lost much of its prognostic value for localeregional relapse, and all for progression-free survival, when primary MTV was added to the model. Akaike information criterion is lowest when primary MTV remained as a single variable in the model. Collinearity was not an issue, with the variance inflation factor limited to 1.27.
Subgroup analysis for p16-positive oropharynx cases
Primary MTV and total MTV remained prognostic in patients with p16-associated oropharyngeal cancer (Table E2 , available online at www.redjournal.com). This ability was associated exclusively with MTV; SUVmax and SUVpeak remained nonprognostic.
Discussion
A mixed picture has emerged regarding utility of FDGPETederived imaging biomarkers in head-and-neck cancer. Although older series suggest poor outcomes in patients presenting with highly elevated SUV values (11) (12) (13) , prospective institutional data (14) suggest that baseline SUVmax and SUVpeak values are not prognostic, either in unselected patients or in patients with HPVassociated oropharyngeal disease. In fact, our present results from RTOG 0522 alternatively suggest better Abbreviations as in Table 2 .
Hazard ratios estimated from Cox models.
locoregional control and progression-free survival in patients presenting with primary SUVmax above the median value for the study cohort (Table 3) . Whether this reflects statistical noise from a small sample or true limitations of SUV-based measures, it is clear that validation of a more robust FDG-PETedefined biomarker could be of considerable clinical value, complementing the incrementally improved staging accuracy of PET/CT. Metabolic tumor volume is a novel PET-specific measure, which incorporates complementary information relevant to both disease burden (akin to clinical stage and CT-derived tumor volume, which are prognostic for outcomes [25, 26] ) and tumor metabolic activity. Although the size of our dataset is limited, our findings add to an emerging literature, which suggests that high primary MTV is associated with localeregional relapse and reduced progression-free survival after radiation therapy.
Despite expected correlation of primary MTV with T stage (15) , earlier reports suggest that MTV dominates univariate and multivariate models of treatment outcome, independent of T stage or human papillomavirus (HPV) infection status (16, 17) . Interestingly, these same reports also suggest lack of utility for SUV values and nodal MTV. Although formal multivariate analysis was not deemed appropriate owing to limited events, the effect of primary MTV was independent of age, gender, Zubrod performance status, pack-years, T stage, and N stage in bivariate analysis. Additionally, although elevated primary MTV was strongly associated with regional and distant disease failure in our series, nodal MTV remained nonprognostic. Although tempting to speculate that biology and tissue architecture specific to nodal disease (such as cystic adenopathy seen in HPV-associated disease) confounds productive use of MTV in regional disease sites, this requires follow-up study for definitive characterization. Along this vein, closer correlation of primary MTV with locoregional/distant disease failure than with local failure (Table 4 ) is in keeping with prior reported data (17) and suggests need for complementary work to mechanistically explain the exact biological significance of primary MTV.
Pretreatment imaging biomarkers can potentially direct personalized treatment intensity. Our findings also suggest that intraobserver PET reading consistency is best in the pretreatment setting. Both issues are of relevance to HPVassociated oropharyngeal disease, which typically responds briskly to treatment and may benefit from pretreatment PET-guided deintensification strategies to limit toxicity. Seven of 8 oropharyngeal cancer relapses in the PET imaging analysis cohort were p16-positive. These 7 patients suffered recurrences in varied locations: 1 tumor recurred in the primary site, 4 recurred in the neck, 1 recurred locoregionally, and 1 recurred both locoregionally and distantly. Six of these 7 patients had discordant abovemedian baseline primary MTV values in the face of belowmedian baseline SUVmax. This spotlights the candidacy of MTV as an imaging-based identifier of "intermediate-risk" p16-positive disease (27, 28) (ie HPV-associated oropharynx patients with bulky primary tumor and/or traditional risk-factor exposure history who suffer inferior treatment outcomes and are not appropriate for deintensified therapy). Nonetheless, this remains an early hypothesis-generating result subject to the potential biases and study power limitations of unplanned subgroup analysis. Formal testing in future multicenter trials is mandatory for validation. Presence of a strong prognostic signal for MTV in our small, heterogeneous study cohort is encouraging. Nonetheless, MTV has limitations as a candidate imaging biomarker. No standard definition for MTV currently exists. Earlier series have used variable, arbitrarily defined percent primary and nodal SUVmax cutoffs to delineate MTV. Accordingly, the relative prognostic performance of specific MTV cutoff values is difficult to compare across published series. In addition, practical use of MTV after treatment is challenging given return of responding tumor sites to background tracer uptake levels. Although prior pilot work supports the use of a posttreatment MTV threshold of SUV Z 2.0 (29), this could not be feasibly reproduced in this study with commercially available software. Future confirmatory work remains necessary.
Another key limitation of our findings is that formal participation of patients enrolled onto the RTOG 0522 trial was limited to 116 patients, and that only 74 of these patients had a full complement of serial imaging available for the analysis specified by protocol. Although reasons for low participation remain speculative, the resulting small sample size suffers from limited statistical power and potential provider-dependent selection biases. Fortunately, the clinical characteristics of the subgroup match reasonably with those of the eligible population as a whole (Table 1) , suggesting broader applicability of our findings to the general head-and-neck radiation therapy patient population. Similar study power issues also impact our secondary subgroup analysis of p16-positive patients. Abbreviations as in Table 2 .
Hazard ratios estimated from Cox models. Abbreviation: AIC Z Akaike information criterion. Other abbreviations as in Table 2 .
To conclude, we found a unique prognostic signal for primary tumor FDG-PETederived MTV in patients with locally advanced head-and-neck cancer. This finding remains preliminary and requires technical refinement and clinical confirmation. There is growing need to better match resource-intensive treatment to individual patient risk. Validation of MTV, a straightforward, noninvasive measure derived from routine workup imaging, could be an important step toward accomplishing this goal.
